Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer
Loading...
Date
Journal Title
Journal ISSN
Volume Title
dc.identifier.issn
dc.identifier.doi
10.1007/s00404-013-2924-7
dc.identifier.other
WOS:000326884700035
dc.description.volume
dc.description.issue
Publisher
SPRINGER HEIDELBERG
DOI
10.1007/s00404-013-2924-7